Beneficial effect of botulinum A toxin in blepharospasm: 16 months' experience with 16 cases

Maurri, S.; Brogelli, S.; Alfieri, G; Barontini, F

doi:10.1007/bf02333996

Cited by 7 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results in patients affected by blepharospasm are in keeping with 16.4 100 91 [11] other reports [23]. As shown in table 5, in earlier studies a clinical improvement w'as observed in 69-100% of pa tients treated for blepharospasm.…”

Section: Discussionsupporting

confidence: 81%

Botulinum Toxin as a Treatment for Blepharospasm, Spasmodic Torticollis and Hemifacial Spasm

et al. 1992

View full text Add to dashboard Cite

Fifty-two patients affected by focal dystonia or hemifacial spasm were treated with repeated injections of botulinum toxin. A clinical improvement was observed in all patients with blepharospasm; clinical benefit had a mean duration of 10 weeks. Clinical results were less inpressive, but also favorable in patients affected by spasmodic torticollis and by hemifacial spasm. In the latter, the incidence of drug-induced paresis was much higher than that observed in patients with blepharospasm, even though the doses of toxin injected were significantly lower.

show abstract

Section: Discussionsupporting

confidence: 81%

Botulinum Toxin as a Treatment for Blepharospasm, Spasmodic Torticollis and Hemifacial Spasm

et al. 1992

View full text Add to dashboard Cite

show abstract

“…The onset of beneficial effect, peak effect and duration of clinical benefit in response to BTX-A are comparable with those observed, by various investigations who used botulinum toxin to treat dystonias, muscle cramps, spasticity and rigidity. 12,14,16,[24][25][26][27] The mean value for reappearance of significant spasms (in months) in the included cases was 5.0 (+ 1.7 Std. deviation, range 2-8).…”

Section: Discussionmentioning

confidence: 99%

The role of the injection Botulinum Toxin A in cases of Essential Blepharospasm Syndrome, Hemifacial Spasm and Meige’s Syndrome

Bastola¹,

Chaudhary

Agrawal

et al. 2012

Kathmandu Univ. Med. J.

View full text Add to dashboard Cite

Background Benign Essential Blepharospasm Symdrome is a neuropathologic disorder. The cause of blepharospasm is multifactorial. It is unlikely that a single defect in this elusive control centre is the primary cause of this disease. Objectives To evaluate the role of botulinum toxin A in treating cases of Essential Blepharospasm Symdrome, Hemifacial Spasm and Meige’s Syndrome, and to assess orbicularis oculi muscle post treatment, in the patients who attended neuro-ophthalmology clinic and the general outpatient department of BP Koirala Lions Centre for Ophthalmic studies. Methods A prospective, interventional study was carried out on all the patients of Essential Blepharospasm Symdrome, Hemifacial Spasm and Meige’s syndrome who underwent treatment with botulinum toxin A in BP Koirala Lions Centre for Ophthalmic studies during a study period of one and half years. Pre- treatment grading of the spasm was done with Jankovic spasm grading and post treatment response was seen with assessment of orbicularis oculi muscle and improvement in functional impairment scale. Relevant findings were noted. Results A total of 40 cases were enrolled in the study. The mean Jankovic spasm grading in cases of essential blepharospasm, hemifacial spasm and Meige’s syndrome was 3.61 (±Standard deviation 0.50, range 3-4), 3.21 (±Standard deviation 0.63, range 2-4) and 3.67 (+- Standard deviation 0.57, range 3-4) respectively. The mean value for reappearance of significant spasms (in months) in cases of essential blepharospasm, hemifacial spasm and Meige’s syndrome was 4.3 (± Standard deviation 1.6, range 2.0-6.5), 5.8 (±Standard deviation 1.4, range 3-8) and 4.5 (± Std.deviation 2.8, range 2.5-6.5) respectively. Blepharoptosis was the commonest complication accounting for 66.6% of the complications.Conclusions The movement disorders like Essential Blepharospasm, Hemifacial Hpasm and Meige’s syndrome are treated by different modalities. An acceptable and effective treatment modality has been a long felt need in these cases. Our study has shown that injection of botulinum toxin A has been a safe and effective method of treating these cases in Nepal.DOI: http://dx.doi.org/10.3126/kumj.v8i3.6217 Kathmandu Univ Med J 2010;8(3):305-10

show abstract

Botulinum A toxin injection in patients with blepharospasm, torticollis and hemifacial spasm

et al. 1990

View full text Add to dashboard Cite

Botulinum A toxin was injected into the affected muscles in 20 patients with blepharospasm, 8 with torticollis and 12 with hemifacial spasm. In all cases blepharospasm and hemifacial spasm was abolished or markedly reduced. The only side effect was transient ptosis and diplopia. Patients with torticollis had a mild to moderate improvement of the dystonic posture and pain; dysphagia was the most troublesome side effect. Botulinum A toxin is an effective therapy in patients with focal dystonia and spasms.

show abstract

Beneficial effect of botulinum A toxin in blepharospasm: 16 months' experience with 16 cases

Cited by 7 publications

References 28 publications

Botulinum Toxin as a Treatment for Blepharospasm, Spasmodic Torticollis and Hemifacial Spasm

Botulinum Toxin as a Treatment for Blepharospasm, Spasmodic Torticollis and Hemifacial Spasm

The role of the injection Botulinum Toxin A in cases of Essential Blepharospasm Syndrome, Hemifacial Spasm and Meige’s Syndrome

Botulinum A toxin injection in patients with blepharospasm, torticollis and hemifacial spasm

Contact Info

Product

Resources

About